Surgery Partners, Inc. SGRY
23.13 USD +0.01 (+0.04%)
At closeNov 3, 2026, 4:01 PM EST
23.13 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
23.12 Day range 23.22
11.41 52-week range 23.37
- YTD
- +49.71%
- 1 year
- +6.59%
Analyst view
Consensus: buy
Buy
Price target (mean) 21.70 -6.2% downside
Now 23.13
- Target (low)
- 19.00
- Target (mean)
- 21.70
- Target (high)
- 23.50
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy0
- Buy2
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 12
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.12467 | 0.07 – 0.20 | 0.13 | -4.1% | 814.70M | -0.8% | 5 |
| Next quarter | 0.15486 | 0.02429 – 0.33 | 0.12 | +29.0% | 680.50M | -23.1% | 5 |
| Current year | 0.35596 | 0.21981 – 0.60 | 0.47 | -24.3% | 3.15B | -4.7% | 5 |
| Next year | 0.20815 | 0.03 – 0.43 | 0.35596 | -41.5% | 2.80B | -11.2% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | UBS | Downgrade | Buy | Neutral |
| Oct 27, 2026 | StoneX | Downgrade | Buy | Hold |
| Sep 30, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Sep 18, 2026 | TD Cowen | Reiterated | Buy | Buy |
| Sep 14, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Aug 11, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 11, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 11, 2026 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Mar 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| Mar 5, 2026 | UBS | Maintained | Buy | Buy |
| Mar 5, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 4, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Mar 3, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Dec 18, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Nov 24, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 21, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Nov 17, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Nov 13, 2025 | UBS | Maintained | Buy | Buy |
| Nov 11, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 11, 2025 | Benchmark | Maintained | Buy | Buy |
| Oct 7, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 27, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Apr 21, 2025 | Benchmark | Reiterated | Buy | Buy |
| Mar 25, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| Mar 11, 2025 | Macquarie | Maintained | Outperform | Outperform |
| Dec 3, 2024 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 20, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 19, 2024 | Macquarie | Maintained | Outperform | Outperform |
| Nov 13, 2024 | Macquarie | Maintained | Outperform | Outperform |
| Nov 4, 2024 | Macquarie | Maintained | Outperform | Outperform |
